NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Wave Life Sciences, Inc. (WVE) Stock Analysis

Wave Life Sciences, Inc. (WVE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

WVE

$3.37

−$0.05 (−1.46%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WVE with… →

WVE Key Statistics

As of Oct 21, 2026
Trading
Open
$3.42
Previous Close
$3.42
Day's Range
3.35–3.48
52-Week Range
3.04–21.73
Volume
2.17M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.43
Valuation
Market Cap
$664.05M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.16
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.08
Financials (FY)
Revenue (FY)
$42.73M−60.55%
Net Income (FY)
−$204.38M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
197.05M
1-Year Return
−57.07%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
3.22M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, WVE closed at $3.37, −57.07% over 1 year.

Wave Life Sciences, Inc. (WVE) has a market capitalization of $664.05M.

In fiscal 2025, WVE reported revenue of $42.73M.

WVE Stock Return by Calendar Year

Wave Life Sciences, Inc. (WVE) 10-year return: what $10,000 became

1 year
$10,000 $4,293
−57.07%
5 years
$10,000 $7,677
−23.23%
10 years
$10,000 $1,118
−88.82%

If you had invested $10,000 in Wave Life Sciences, Inc. (WVE) 10 years ago, at the close on October 21, 2016, it would have been worth $1,118 at the close on October 21, 2026: −88.82% in total, −19.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−80.18%
2025+37.43%
2024+144.95%
2023−27.86%
2022+122.93%
2021−60.10%
2020−1.87%
2019−80.92%
2018+19.77%
2017+34.23%
2016 (partial year)+34.17%

As of October 21, 2026.

WVE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$42.73M−$204.38M−478.3%
2024$108.30M−$97.01M−89.6%
2023$113.31M−$57.51M−50.8%
2022$3.65M−$161.82M−4,434.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$42.73M—−$215.38M−$204.38M−478.3%
2024$108.30M—−$110.40M−$97.01M−89.6%
2023$113.31M—−$68.00M−$57.51M−50.8%
2022$3.65M—−$162.72M−$161.82M−4,434.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

WVE Valuation vs Biotechnology Median

Median of 608 stocks
MetricWVEBiotechnology medianvs median
P/S ratio10.1613.3024% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Wave Life Sciences, Inc. (WVE) is capitalised at $664.05M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 317 employees.

Over the past 52 weeks the price has ranged from $3.04 to $21.73. WVE last closed at $3.37 on October 21, 2026. That is −$0.05 (−1.46%) against the previous close. The latest close sits 10.86% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $42.73M. Against the prior fiscal year total of $108.30M, that is a change of −60.55%. The same year closed with a net loss of $204.38M. Trailing earnings per share are −1.08.

Across the 4 fiscal years on file, revenue moves from $3.65M in 2022 to $42.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 10.16 times revenue. On price-to-sales that is 23.61% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −57.07%. Measured over 10 years, that is −19.68% a year compounded. Beta against the wider market is reported at −1.43. Daily returns over the trailing 10 years annualize to a volatility of 98.74%.

Growth & Income

The record shows no dividend for WVE.

Across the complete calendar years on file, 2024 returned +144.95% and 2019 returned −80.92%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the total return is −80.18%.

Peer Comparison

Wave Life Sciences, Inc. (WVE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Wave Life Sciences, Inc. WVE $664.05M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Wave Life Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Wave Life Sciences, Inc.

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Visit website →